Skip to content
Screener

Supernus Pharmaceuticals SUPN Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$2.47M+40.6%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$14.31M+22.4%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$646K+91.7%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$57.3M+25.7%
XER
Xeris Biopharma Holdings, Inc.XERS
$6.31M+2.5%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$58.8M+25.0%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.77B+20.4%
Enterprise value$2.63B+19.9%
P/S3.6×+0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemBalance Sheet ClassificationMarch 31, 2026December 31, 2025
(unaudited)
Assets
Operating lease assetsOther assets$26,397$26,712
Total lease assets$26,397$26,712
Liabilities
Operating lease liabilities, current portionAccounts payable and accrued liabilities$10,636$10,612
Operating lease liabilities, long-termOperating lease liabilities, long-term30,26730,365
Total lease liabilities$40,903$40,977

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's operating lease liabilities (current)?
Supernus Pharmaceuticals (SUPN) reported operating lease liabilities (current) of $10.64M in Q1 2026.
How has Supernus Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
Supernus Pharmaceuticals's operating lease liabilities (current) increased by 79.1% year-over-year, from $5.94M to $10.64M.
What is the long-term trend for Supernus Pharmaceuticals's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Supernus Pharmaceuticals's operating lease liabilities (current) has grown at a 23.1% compound annual growth rate (CAGR), from $3.76M to $10.61M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Supernus Pharmaceuticals's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude